CUL4B

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, CUL4B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CUL4B data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CUL4B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CUL4B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, PAAD, and PRAD are the cancer types where CUL4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
UCECDFSMedianII,III,IV0.9480.297.00236view →
PAADOSMedianAll0.0600.641<.00112view →
PRADDFSMedianAll0.0850.774<.0016view →
STADOSMedianAll0.1230.540.0383view →
HNSCOSMedianAll0.4160.663.0413view →
SKCMDFSMedianIII,IV0.0460.648<.0013view →
LUSCDFSMedianAll0.4300.799.0212view →
Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CUL4B–UCEC (DFS)

Kaplan–Meier survival curve for CUL4B mutant vs wild-type samples in UCEC.

Open the UCEC breakdown →

Exploration